There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as ...

PROTACs enable targeting of previously "undruggable" proteins, offering potential treatments for challenging cancers and drug-resistant conditions. Major pharmaceutical companies are investing in ...

TORONTO -- A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data. The ...

An innovative blood cancer treatment regime could extend remission by seven months on average, according to a clinical trial led by the University of Leeds. Myeloma, a blood cancer that accounts for 1 ...

Consolidation and maintenance therapy with Ninlaro post-HSCT significantly improves progression-free survival compared to observation in relapsed multiple myeloma patients. The Myeloma XII (ACCorD) ...

A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice. The ...

The 68-year-old patient had multiple myeloma and breast cancer. A new case report details a complete pathological response to a 3-month combination therapy of ixazomib, bendamustine, and dexamethasone ...

A new oral treatment combination for multiple myeloma, a treatment option for some adults with hereditary transthyretin-related amyloidosis (hATTR), and gene therapy for Duchenne muscular dystrophy, ...

Years of laboratory work have revealed how a marine bacterium makes a potent anticancer molecule called salinosporamide. Researchers at UC San Diego’s Scripps Institution of Oceanography unravelled ...

Prasad: I'm back -- new abstract, again talking to Aaron Goodman, Manni Mohyuddin. Ixazomib plus len/dex [lenalidomide/dexamethasone] versus len/dex maintenance after ...

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib ...

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib ...